Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • US Politics
    US Politics
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña




Consumer Daily Reports

The study found the results are even less reliable for black patients

By Mark Huffman Consumer News: Researchers highlight some limitations of new Alzheimer’s blood tests of ConsumerAffairs
February 27, 2025

Recent scientific research has led to a blood test that can predict Alzheimer's disease. However, a new study by Rutgers Health has raised significant concerns about the reliability of Alzheimer's disease blood tests, particularly for Black patients.

The research, led by William Hu, director of the Rutgers Center for Healthy Aging Research, calls for a cautious interpretation of these tests, which are currently marketed to primary care physicians and older adults worried about cognitive decline.

Hu said these tests may offer some value to primary care doctors who understand their limitations, but there is no reason for patients with memory concerns to purchase these tests, which are priced between $1,200 and $2,000 and are rarely covered by insurance.

The study found that concentrations of Alzheimer's biomarkers are notably lower in blood compared to spinal fluid, where they have been validated as diagnostic tools for White patients. This discrepancy is particularly pronounced in Black patients, who naturally have lower biomarker levels in their spinal fluid. Additionally, worse memory function can elevate blood biomarker levels, complicating the test's accuracy.

Mild conditions could go undiagnosed

Hu said the blood tests have many caveats, and that poor transfer of proteins from spinal fluid to blood means many patients will go undiagnosed, especially if their disease is mild, while the ability of other ailments to increase these proteins in the blood can lead to false positives.

The research involved participants from Rutgers and Emory University, including Black, non-Hispanic White, and ethnic Chinese individuals. All 221 participants underwent detailed clinical evaluations and brain imaging, with both blood and spinal fluid samples collected on the same day. Automated testing systems were used to measure levels of specific proteins, particularly p-Tau217.

The study revealed a 70% correlation between protein levels in spinal fluid and blood, with significant racial disparities. For White participants, the blood test showed 90.3% sensitivity and 81.1% specificity, whereas for Black participants, sensitivity dropped to 73.7% and specificity to 72.5%. The positive predictive value was much higher for white participants (87%) compared to Black participants (58%).

Hu noted that while the tests may eventually become reliable, they currently require significant refinement.

Sign up below for The Daily Consumer, our newsletter on the latest consumer news, including recalls, scams, lawsuits and more.




Posted: 2025-02-27 12:38:05

Get Full News Story On Consumer Affairs



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category

Consumer News: Just one night of poor sleep can disrupt your immune system, study finds

Thu, 17 Jul 2025 19:07:07 +0000

New research finds even short-term sleep loss may interfere with the bodys ability to fight infection

By Kristen Dalli of ConsumerAffairs
July 17, 2025
  • Researchers from the University of Washington and the Allen Institute found that missing a single night of sleep can quickly affect key parts of the immune system.

  • The study found important immune cells became overactive after sleep loss.

  • Researchers say even occasional sleep disruption may have bigger health impacts than we think.

Weve all had those nights staying up too late to meet a deadline or tossing and turning until morning. But a new study from researchers at the University of Washington and the Allen Institute reveals that even one night of sleep deprivation may be enough to disrupt how your immune system works.

According to the study, a single 24-hour period without sleep altered the behavior of several types of immune cells in healthy young adults. The findings suggest that short-term sleep loss could make the body more vulnerable to illness even if you're generally healthy and well-rested otherwise.

Our findings underscore a growing public health challenge, researcher Dr. Fatema Al-Rashed said in a news release.

Advancements in technology, prolonged screen time, and shifting societal norms are increasingly disruptive to regular sleeping hours. This disruption in sleep has profound implications for immune health and overall well-being.

The study

To find out how sleep affects the immune system, researchers recruited 11 healthy adults between the ages of 20 and 23. Each participant went through two sessions: one where they slept normally and another where they stayed awake for a full 24 hours.

At both sessions, blood samples were taken in the morning to analyze immune activity. The researchers used a detailed genetic analysis technique called single-cell RNA sequencing to study how individual immune cells were behaving after the night of sleep deprivation compared to a normal nights sleep.

The goal was to track whether missing sleep would alter the activity of immune cells especially those responsible for inflammation and responding to infections.

The results

The results were clear: after just one night without sleep, participants showed big changes in their immune cell activity.

Researchers observed that two types of immune cells monocytes and T cells became more active. These cells play key roles in detecting and responding to infections. But in this case, the immune response looked revved up, even without any actual illness present.

The researchers explained that the immune system reacted to sleep loss like it was under threat, even though there was no infection. This kind of overactivation can be a problem over time. If immune cells are constantly in a heightened state, it may lead to chronic inflammation or make it harder for the body to respond appropriately to real threats.

The researchers noted that while more studies are needed to understand long-term effects, this experiment shows how sensitive the immune system is to sleep changes even after just one sleepless night.

In the long term, we aim for this research to drive policies and strategies that recognize the critical role of sleep in public health, Dr. Al-Rashed said.

We envision workplace reforms and educational campaigns promoting better sleep practices, particularly for populations at risk of sleep disruption due to technological and occupational demands. Ultimately, this could help mitigate the burden of inflammatory diseases like obesity, diabetes, and cardiovascular diseases.


Read More ...


Consumer News: Can the shingles vaccine lower your risk of dementia?

Thu, 17 Jul 2025 19:07:07 +0000

New research shows an unexpected link between shingles vaccination and lower dementia risk

By Kristen Dalli of ConsumerAffairs
July 17, 2025

A shingles vaccine was tied to a 20% drop in new dementia cases over seven years.

The U.K. rollout created a natural experiment using birthdate eligibility.

Reduction was especially strong in women, beyond the effects on shingles itself.


Researchers at Stanford Medicine dove into health records from older adults in Wales to explore the link between the shingles vaccine and the risk of dementia.

They focused on those eligible for the live-attenuated shingles vaccine (Zostavax) based on an exact birthdate cutoff: anyone born on or after September 2, 1933 was eligible, while those born just before werent.

Because both groups were nearly identical in age, health, and behavior except for vaccine eligibility this setup acted like a natural randomized trial.

The result? Receiving the shingles vaccine was associated with a 20% lower chance of developing dementia over the next seven years, even after accounting for who actually got vaccinated.

All these associational studies suffer from the basic problem that people who get vaccinated have different health behaviors than those who dont, researcher Pascal Geldsetzer, M.D., Ph.D., said in a news release. In general, theyre seen as not being solid enough evidence to make any recommendations on.

The study

For the study, the researchers used a regression discontinuity design it allows them to compare people who are alike except for being eligible for vaccination. By looking at those born just before and after the September 1933 cutoff, they ensured both groups were very similar. One group had a 47.2% vaccination rate, while the other had only 0.01%.

Health records were tracked for seven years, noting new dementia diagnoses. To make sure the vaccine itself was the key difference, they checked that the groups didnt differ in other diseases, doctor visits, or preventive health behavior. They even used alternative analyses to confirm the findings held up no matter how they looked at the data .

The study

The researchers found that there were fewer dementia cases overall. Being eligible for the vaccine cut new dementia diagnoses by 1.3 percentage points, or about 8.5% fewer cases.

In participants who actually got the shot, the reduction jumped to 3.5 points, a 20% drop in dementia risk.

It was a really striking finding, Dr. Geldsetzer said in the news release. This huge protective signal was there, any which way you looked at the data.

The team also learned that women had greater protective cognitive benefits than men. Though the vaccine lowered dementia risk for both sexes, the effect was significantly stronger in women.

What this means for you

The findings highlight a bonus to getting your shingles vaccine: the potential to protect your brain. Scientists are still trying to figure out why it works whether its because the vaccine stops inflammation-causing shingles outbreaks, or if the vaccine primes the immune system in a way that wards off dementia.

While the study is robust, with careful methods that reduce bias, its still observational. That means it can show a strong connection, but not absolute proof. The researchers stress the need for randomized clinical trials before making firm claims.


Read More ...


Consumer News: Meta, Flo Health face privacy trial in fertility app case

Thu, 17 Jul 2025 19:07:07 +0000

Potential damages could reach billions under California laws

By James R. Hood of ConsumerAffairs
July 17, 2025
  • Class action trial looms over claims Flo shared intimate user data with Meta without consent
  • Potential damages could reach billions under California privacy laws

  • Google has settled; Meta and Flo may face jury in San Francisco starting July 21


Fertility tracking app Flo Health and tech giant Meta are set to face a high-stakes class action trial next week in federal court in San Francisco over claims they violated user privacy by sharing sensitive reproductive health data without adequate consent.

At the center of the controversy: deeply personal questions allegedly posed to users from menstrual cycle dates to sexual activity, masturbation habits, and infections and the subsequent unauthorized sharing of this data.

The plaintiffs in the case accuse Flo and Meta, parent of Facebook, of violating the California Invasion of Privacy Act and Californias Confidentiality of Medical Information Act. These laws impose steep statutory fines $5,000 and $1,000 per violation respectively which could lead to staggering financial exposure.

While estimates of the affected user base vary, if the court accepts the plaintiffs high-end figure of 38 million class members, Meta alone could face up to $190 billion in liability. Flo, which suggested that the total could be lower, still warned of theoretical damages reaching quadrillions if each app entry is counted as a separate infraction.

Meta has dismissed the claims as baseless, asserting that it neither wants nor allows developers to send sensitive health data and that the evidence will show it did not intentionally intercept any communications. Flo, a London-based private company, also denies wrongdoing, maintaining that its users were informed through privacy disclosures and gave implied consent.

The lawsuit stems from a 2019 Wall Street Journal investigation, which revealed that Facebook was receiving private health information from the Flo app. That prompted an FTC investigation, which culminated in a 2021 settlement requiring Flo to notify users and obtain their consent before sharing such data in the future.


Read More ...


Consumer News: Elderly men most at risk of dying by suicide

Thu, 17 Jul 2025 19:07:07 +0000

Older men are often lonely ... and they have guns and know how to use them

By Truman Lewis of ConsumerAffairs
July 17, 2025
  • While youth suicide has declined after public health focus, suicide rates among men 75+ remain alarmingly high
  • Men over 85 die by suicide at rates more than 50 times higher than women, often via firearms

  • Experts urge a national prevention strategy tailored to aging men, countering stigma and isolation


After years of intensifying concern over youth mental health including a 2021 warning from the U.S. surgeon general and a declaration of crisis from the American Psychological Association the suicide rate among teens and young adults began to fall in 2022 and 2023. That success, experts say, stems from a flood of advocacy, media attention, and public health investment.

But while young people received national attention, the group most at risk of dying by suicide wentlargely unnoticed: older men, particularly those aged 75 and above, according to studies quoted by Statnews.

An overlooked demographic,deadly risk

According to the Centers for Disease Control and Prevention, suicide rates for men aged 75 to 84 reached 38.2 per 100,000 in 2021, rising to 55.7 per 100,000 among those 85 and older a rate more than 16 times higher than their female peers. These are the highest suicide rates of any demographic group in the United States.

Despite the staggering figures, older adults have been left out of most national suicide prevention efforts.

Why Are Older Men Dying by Suicide?

Experts point to a complex web of factors, including:

  • Access to firearms, the most lethal method of suicide. Guns were responsible for suicide death rates 17 times higher among men than women aged 7584, and 51 times higher among men 85+.

  • Masculine socialization, which discourages emotional expression, help-seeking, and reliance on social support.

  • Life changes and stressors like retirement, illness, disability, bereavement, and social disconnection.

Men spend their lives achieving and neglecting social connections, said Igor Galynker, psychiatry professor at Mount Sinai. When they retire, they lose both their social life and sense of purpose.

Research shows that older women, by contrast, are more adept at building and maintaining support networks, are more likely to recognize depressive symptoms, and are more inclined to seek mental health care.

Worried about someone?

If you're concerned about someone, suicide prevention resources are available, including the 988 Suicide & Crisis Lifeline (call or text 988). Early intervention and social support can be life-saving.


Read More ...


Consumer News: Bristol-Myers, Pfizer slash Eliquis price for cash-paying patients

Thu, 17 Jul 2025 19:07:07 +0000

But the lower price is still higher than insurance, Medicare and overseas rates

By Truman Lewis of ConsumerAffairs
July 17, 2025
  • Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs
  • New $346 monthly price remains far higher than what insured or Medicare patients pay

  • Move comes amid Trump administration pressure to align U.S. drug prices with global rates


In a direct-to-patient move likely to reverberate across the pharmaceutical landscape, Bristol-Myers Squibb and Pfizer announced today they will begin offering their blockbuster blood thinner Eliquis at a discount to U.S. patients who pay out of pocket cutting out traditional pharmacy benefit managers (PBMs) and insurers.

Starting September 8, eligible patients can buy Eliquis through the Eliquis 360 Support program for $346 per month, a 43% discount from its current list price of about $606. The initiative is designed to increase access for uninsured or underinsured patients, providing what the companies call transparent pricing and direct support.

"While more than 90% of Eliquis prescriptions in the U.S. are currently covered through insurance," the companies said in a statement, "this program expands affordability options for cash-paying patients."

Critics say discount still falls short

However, the discount may be more symbolic than substantial, especially when compared to prices negotiated through government programs or charged abroad.

  • Commercially insured U.S. patients typically pay much less than $346 out of pocket due to negotiated copays.

  • Medicare recipients, under a pricing agreement enacted by the Inflation Reduction Act (IRA), will begin paying just $231 a month starting next year.

  • International prices for Eliquis are even lower: according to a 2024 Senate HELP Committee report, the drug costs about $55 in France, $65 in the UK, and $65 in Germany.

Trump administration applies pressure

The new pricing plan comes amid renewed scrutiny from the Trump administration, which is pushing for lower U.S. drug prices through its revived most-favored-nation (MFN) policy. That effort aims to peg domestic prices to the lowest rates paid by other high-income countries, a policy that could significantly undercut many U.S. list prices.

While the administration has not yet commented on the Eliquis move, it has previously expressed skepticism toward industry-led discount programs that do not fully bridge the pricing gap with other nations.

A lucrative drug with broad reach

Since its launch, Eliquis has been prescribed to over 15 million Americans, primarily to prevent strokes and blood clots in patients with atrial fibrillation or certain other conditions. In 2024, the drug generated approximately $11.4 billion in global revenue, making it one of the top-selling medications worldwide.


Read More ...


Related Bing News Results

Consumer Spending Update: Economic Confidence Hits 4-Year High in July

Mon, 14 Jul 2025 10:16:00 GMT
Economic confidence increased to 115.9 in this month’s Rasmussen Reports Economic Index, more than three points higher than June.

A key piece of the next consumer-price report risks upsetting the bond market

Thu, 10 Jul 2025 14:39:00 GMT
The next major U.S. inflation report is set to arrive on Tuesday in the form of the consumer-price index for June, and will inform investors as to whether President Donald Trump’s tariff wars with ...

Consumer Reports: The top 2025 cars, trucks and SUVs - WMUR

Thu, 10 Jul 2025 09:11:00 GMT
With more than 260 new vehicles on the market, finding a safe, reliable and budget-friendly car can be challenging.

Consumer Protection - The New York Times

Mon, 07 Jul 2025 17:00:00 GMT
News about Consumer Protection, including commentary and archival articles published in The New York Times.

Consumer Spending Update: Economic Confidence Rises in June

Wed, 11 Jun 2025 17:00:00 GMT
Economic confidence increased to 112.1 in this month’s Rasmussen Reports Economic Index, more than five points lower than in May. Please sign up for the Rasmussen Reports daily e-mail update (it ...


Blow Us A Whistle




Related Product Search/Búsqueda de productos relacionados